Piper Jaffray said GlaxoSmithKline (GSK) may be motivated to acquire Humane Genome Sciences (HGSI) given its valuation discount to Benlysta’s market value. The analyst believes a takeout value would be between $21-$26 per share and maintains its Overweight rating with at new price target of $18, down from $31.
